Copeptin in Autosomal Dominant Polycystic Kidney Disease (AdPKD)

AdPKD (Autosomal Dominant Polycystic Kidney Disease) is the fourth leading cause of end-stage renal disease (ESRD) worldwide but there is high variability in disease progression. Copeptin, an accurate surrogate marker of Vasopressin (AVP), correlates with disease severity in AdPKD, and predicts the decline in renal function and increase in Total Kidney Volume; therefore it may be used to select patients groups who will benefit the most for specific medical or life style treatments options and to monitor the effectiveness of such treatment.


Free webinar about Copeptin in AdPKD (Autosomal Dominant Polycystic Kidney Disease)

Improving prognosis and treatment response in AdPKD: role of Copeptin

This webinar will review the available clinical evidences and the ongoing studies that will support establishing Copeptin as a marker in AdPKD.


Find more free webinars on Copeptin >

thermo scientific applied biosystems invitrogen fisher scientific unity lab service